Switch theme
Sign up to access all valuation multiples
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
2010
113
LTM Revenue $1.8M
LTM EBITDA -$130M
$787M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CG Oncology has a last 12-month revenue of $1.8M and a last 12-month EBITDA of -$130M.
In the most recent fiscal year, CG Oncology achieved revenue of $1.1M and an EBITDA of -$115M.
CG Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CG Oncology valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.2M | $1.1M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$55.4M | -$115M | XXX | XXX | XXX |
| EBITDA Margin | -27173% | -10064% | XXX | XXX | XXX |
| Net Profit | -$35.4M | -$48.6M | XXX | XXX | XXX |
| Net Margin | -17374% | -4268% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, CG Oncology's stock price is $20.
CG Oncology has current market cap of $1.5B, and EV of $787M.
See CG Oncology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $787M | $1.5B | XXX | XXX | XXX | XXX | $-1.52 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, CG Oncology has market cap of $1.5B and EV of $787M.
CG Oncology's trades at 435.7x LTM EV/Revenue multiple, and -6.1x LTM EBITDA.
Analysts estimate CG Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for CG Oncology and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $787M | XXX | XXX | XXX |
| EV/Revenue | 691.1x | XXX | XXX | XXX |
| EV/EBITDA | -6.9x | XXX | XXX | XXX |
| P/E | -17.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -10.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCG Oncology's NTM/LTM revenue growth is 1697%
CG Oncology's revenue per employee for the last fiscal year averaged $10K, while opex per employee averaged $1.0M for the same period.
Over next 12 months, CG Oncology's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate CG Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for CG Oncology and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 458% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -10064% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 107% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -8368% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $10K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2959% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7208% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 10167% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CG Oncology acquired XXX companies to date.
Last acquisition by CG Oncology was XXXXXXXX, XXXXX XXXXX XXXXXX . CG Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was CG Oncology founded? | CG Oncology was founded in 2010. |
| Where is CG Oncology headquartered? | CG Oncology is headquartered in United States of America. |
| How many employees does CG Oncology have? | As of today, CG Oncology has 113 employees. |
| Who is the CEO of CG Oncology? | CG Oncology's CEO is Mr. Arthur Kuan. |
| Is CG Oncology publicy listed? | Yes, CG Oncology is a public company listed on NAS. |
| What is the stock symbol of CG Oncology? | CG Oncology trades under CGON ticker. |
| When did CG Oncology go public? | CG Oncology went public in 2024. |
| Who are competitors of CG Oncology? | Similar companies to CG Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of CG Oncology? | CG Oncology's current market cap is $1.5B |
| What is the current revenue of CG Oncology? | CG Oncology's last 12-month revenue is $1.8M. |
| What is the current EBITDA of CG Oncology? | CG Oncology's last 12-month EBITDA is -$130M. |
| What is the current EV/Revenue multiple of CG Oncology? | Current revenue multiple of CG Oncology is 435.7x. |
| What is the current EV/EBITDA multiple of CG Oncology? | Current EBITDA multiple of CG Oncology is -6.1x. |
| What is the current revenue growth of CG Oncology? | CG Oncology revenue growth between 2023 and 2024 was 458%. |
| Is CG Oncology profitable? | Yes, CG Oncology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
